JCM
EBS icon

JS Capital Management’s Emergent Biosolutions EBS Stock Holding History

JS Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,600
Closed -$364K – 168
2020
Q2 		$364K Buy
+4,600
New +$343K 0.03% 102

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

JS Capital Management's EBS Position: Q3 2020 in Review

JS Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 4,600 shares — an estimated $364K sold.

JS Capital Management first reported a position in EBS in Q2 2020 and held it in 1 quarter. The position peaked at $364K in Q2 2020. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

  • JS Capital Management reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
  • JS Capital Management sold 4,600 Emergent Biosolutions shares in Q3 2020, an estimated $364K.
  • JS Capital Management first reported a position in Emergent Biosolutions in Q2 2020 and held it in 1 quarter.
  • JS Capital Management's Emergent Biosolutions position peaked at $364K in Q2 2020.
  • 358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on JS Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.